Coronavirus / COVID

COVID-19 disease severity was mild in individuals in Qatar infected with the Omicron BA.1 and BA.2 sublineages with vaccination and booster doses reducing risks even further, a new study showed.

Valneva’s COVID-19 vaccine candidate, VLA2001, demonstrated superior virus-neutralizing antibodies compared to the AstraZeneca vaccine.

"Real-world" population study finds the oral antivirals authorized for non-hospitalized COVID-19 patients can benefit when started in the hospital.

Catch up on all the important news and clinical care topics you may have missed this week.

The federal agency's recommendation for both the Moderna and the Pfizer-BioNTech updated bivalent vaccines allows people to get the booster dose this fall.

This Emergency Use Authorization for the Moderna and Pfizer-BioNTech vaccines brings them both one step closer for people to become eligible for these boosters.

Oral antiviral nirmatrelvir/ritonavir is shown to be effective treatment for seniors against Omicron.

AIVITA’s COVID-19 vaccine candidate contains only the subject’s primed immune cells.

A new study found that patients hospitalized with COVID-19 are at significantly higher risk for venous thromboembolism in the ensuing 3 months than are patients hospitalized with influenza.

A study published this week by the American Heart Association found myocarditis was more common after COVID-19 infection than after COVID-19 vaccination.

The Cambridge-MA., company accuses Pfizer and BioNTech of copying patented technology in the development of their COVID-19 vaccine.

Pfizer-BioNTech and Moderna have developed new booster shots optimized for Omicron. They could be approved as soon as Labor Day.

If granted the Emergency Use Authorization (EUA), this vaccine would be available for individuals 18 years and older.

Read this week’s top infectious disease stories you may have missed, including Dr. Anthony Fauci’s announcement.

The companies are requesting the Emergency Use Authorization (EUA) for 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

Guest author Seth Lederman, MD, calls Long COVID "one of the most pressing global health threats I have seen since fighting HIV/AIDS."

A third dose of mRNA COVID-19 vaccines may allow most immune compromised patients with hematologic cancers to achieve antibody response levels similar to those of healthy adults after a two-dose series.

People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.

56% of adults with evidence of Omicron seropositivity did not know they were infected.

Durable immune responses are seen in all age groups, even with significant discrepancies in antibody levels between children and adults.

Risk of severe maternal morbidity was highest during the period when Delta was the predominant COVID-19 variant.

If it is granted an Emergency Use Authorization (EUA), the vaccine could be used as a booster dose for individuals 18 years and older vaccinated with any of the other available COVID-19 vaccines.

Investigators sought to address the effectiveness of vaccination after COVID-19 recovery.

6 months after acute COVID-19 infection, patients had elevated usage of health care services to treat post-COVID conditions.

The booster is designed for immunization against the original wild strain as well as Omicron variant.

Neutralization of BA.4 and BA.5 dropped significantly for individuals who were infected with a previous strain of Omicron, even if they were also vaccinated.

Asymptomatic individuals in low-risk settings do not have to quarantine after COVID-19 exposure, CDC says.

The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.

The findings come from a large Dutch study and demonstrate the symptoms of the virus months after people's acute infections.